Codexis (CDXS) Q3 2026 earnings review
Codexis enzyme sales more than double, and debt refinancing extends cash
Codexis, a maker of custom enzymes for manufacturing medicines, grew rapidly as its older pharmaceutical business rebounded and costs fell. Third-quarter sales more than doubled from a year ago to $19 million, and product gross margin rose 10.5 percentage points as customers launched newer, more profitable drugs. Chief executive Alison Moore kept the full-year sales plan unchanged, which by our math leaves about $25 million for the fourth quarter.
| Total revenue | $19.3M +124% from a year ago (+29% from Q2) |
|---|---|
| Product gross margin | 74.5% +10.5 percentage points from a year ago |
| Net loss | $8.1M narrowed from $19.6M a year ago |
| Full-year outlook | Margin raised revenue held at $72–76M; margin now low 70% range |
⚖️ Verdict: 🟢 Bullish
The story got better because the rebound in enzyme sales and the November debt refinancing eased the company's biggest balance-sheet risks. Replacing the old loan pushes cash runway through 2028, while new conference data showed its RNA manufacturing platform produces more potent drug material at a 100-gram scale. One caution: the start of construction on its clinical factory slipped into next year, and no major commercial RNA contract has closed yet.
The question now is whether Codexis can reach its full-year sales target through regular enzyme orders or still needs a one-off licensing deal before December. If customer drug launches carry the fourth quarter, the core business can fund the RNA build-out; if sales fall short, the back-half plan was too ambitious. Fourth-quarter revenue and any year-end contract announcements will settle it.
🐂 Bull Case
New Customer Drug Approvals Lifted Enzyme Sales
Codexis makes custom enzymes that drugmakers use to produce small-molecule medicines. Management de-emphasized parts of this older business last year, but recent drug approvals among its customers are now lifting both revenue and profitability. The company said the jump was "driven by the approval and launch of new products by our customers with higher margins compared to more established products".
- Product revenue: $15.7 million, up 131.2% from a year ago and 19.1% from last quarter
- Product gross margin: 74.5%, up 10.5 percentage points from 64.0% a year ago
- Full-year gross margin outlook: raised to the low 70% range from the high 60% range
This matters because the enzyme business is funding the company while its newer RNA manufacturing technology remains in early testing. Nine-month product gross margin reached 73.5% by our math, because newer branded drugs pay better prices than older medicines that are winding down.
What to watch: fourth-quarter product revenue against the $15.7 million third-quarter level. Another sequential rise would show that recurring commercial drug launches, rather than one-time launch stockpiling by a few buyers, are driving the recovery.
New RNA Data Showed Stronger Potency at Scale
Codexis is developing ECO Synthesis, a water-based enzymatic system to manufacture short interfering RNA (siRNA) drugs instead of using harsh chemical solvents. Chief executive Alison Moore highlighted presentations at the TIDES Europe conference "showing successful scale-up of the ECO Synthesis® Manufacturing Platform at 100-gram scale with high product quality" and shorter production cycle times.
Crucially, the company also presented test data showing "greater potency of stereo-defined siRNA as compared to chemically synthesized material", and signed an October feasibility study with an siRNA developer to purify fragments. Until now, it was unclear whether controlling the exact shape of RNA molecules actually made drugs work better, so proof of higher potency gives drugmakers a clinical reason to switch.
What to watch: whether Codexis reaches its 500-gram pilot production goal by year-end. Hitting half a kilogram would keep the technical scale-up on schedule before its clinical factory opens.
Refinancing and Cost Cuts Extend Cash Runway
A standing risk for Codexis has been its cash burn, share dilution, and an old $40 million loan that started requiring principal payments in early 2027. Moore said the company is "improving the financial stability of our company" after raising $25 million from a July stock sale and signing a new $60 million loan with Trinity Capital in November, using $42.5 million at closing to pay off the old debt.
Lower operating costs also narrowed the quarterly net loss from $19.6 million a year ago to $8.1 million. Research and development spending fell from 161.2% of revenue to 65.3% by our math, and administrative overhead dropped from 130.4% to 52.4% because of last year's staff cuts. The company ended September with $72.7 million in cash and short-term investments and expects to fund operations through 2028.
What to watch: the interest rate, amortization schedule, and revenue covenants on the Trinity Capital loan in the third-quarter filing. Those terms will show how much cash the refinancing actually saves in 2027 and 2028.
🐻 Bear Case
Full-Year Plan Still Needs a Steep Q4 Jump
Codexis kept its full-year revenue outlook at $72 million to $76 million. With $49.4 million booked across the first nine months, the middle of that range leaves $24.6 million for the fourth quarter by our math. Last year's fourth quarter reached $38.9 million only because of a one-time $31.5 million technology transfer fee from Merck; without that fee, underlying fourth-quarter sales were about $7.4 million.
- Nine-month total revenue: $49.4 million, leaving $22.6–26.6 million needed in Q4
- Required Q4 sequential jump: up 27.6% from Q3 at the $24.6 million middle of the range
- Deferred revenue on the balance sheet: $0.74 million, down from $7.37 million at year-end
That leaves a steep climb with very little prepaid work sitting in deferred revenue to back it up. Meanwhile, contract assets—work recorded as revenue before the customer is billed—rose to $8.59 million from $0.49 million at the end of 2025, showing that recent revenue growth already relies heavily on unbilled milestones.
What to watch: fourth-quarter research and development revenue. If Codexis hits its $72–76 million full-year target without a sudden one-off licensing fee, it will prove the enzyme business can carry the company on its own.
Factory Construction and Partner Deals Slipped
Management wants to turn its ECO Synthesis platform into a commercial business by building a clinical-grade factory (the ECO GMP Manufacturing Center) and signing revenue-sharing deals with contract drug manufacturers (CDMOs). Earlier this year, the company planned to start retrofitting the factory in the second half of 2026 and aimed to sign a strategic CDMO agreement and a major pharmaceutical licence by the end of 2026.
Those timelines softened this quarter even as Moore praised the platform's progress. Codexis now expects to "begin retrofit construction for its ECO GMP Manufacturing Center in the new year", pushing the start out of 2026, though it still targets completion by the end of 2027. It also listed "a goal of commencing a strategic partner agreement" with a CDMO without a 2026 deadline, and has still not signed a major licensing contract.
What to watch: an announcement of a signed commercial contract with its lead CDMO partner before year-end. Another quarter without a signed deal would show that technical interest at conferences is taking longer to turn into commercial revenue.
Risks this quarter didn't answer
Three standing concerns from prior quarters cannot be read from the earnings release and await the quarterly filing or conference call.
- Customer concentration: two buyers accounted for 52% of revenue last quarter; the filing's customer footnote will show whether Q3's $15.7 million enzyme sales were broader.
- ECO Synthesis revenue in dollars: brought in only $0.7 million in the first half; the filing's revenue breakdown will show if feasibility studies moved the needle.
- ECO customer pipeline count: last reported at over 50 opportunities with 40 companies in Q1 and omitted in Q2; any update on the call will show funnel momentum.
💲 Other KPIs
Share count rose 18.8% from a year ago and 17.8% from the second quarter. The jump reflects the July equity offering that raised about $25 million in net proceeds. While the cash bolstered the balance sheet, the new shares diluted existing holders by nearly a fifth in a single quarter.
Contract assets—revenue Codexis has recorded for work completed before it can send an invoice—nearly doubled from $4.3 million in the second quarter and rose seventeen-fold from $0.49 million at year-end. Over the same nine months, deferred revenue (cash collected upfront for future work) shrank 90% to $0.74 million.
Combined research and development ($12.6 million) and selling, general and administrative ($10.1 million) spending fell 9.6% from $25.1 million a year ago, and stayed level with $22.6 million in the second quarter. Lower headcount, stock compensation, and lab supply spending offset higher facility costs ahead of the clinical factory build.
🔮 Guidance
Unchanged. The plan calls for 5.1% reported growth at the $74 million middle of the range, or 74.1% growth by our math when stripping the Merck technology transfer fee from both years ($31.5 million in 2025 and $6.3 million in 2026). That leaves $24.6 million for Q4, requiring a 27.6% jump from Q3.
Raised. Management lifted its full-year product gross margin view for a second straight quarter after starts in the mid-60s and high-60s. With nine-month product gross margin already at 73.5% by our math, a full-year finish around 72% allows for a slightly less favourable product mix in the fourth quarter.
❓ Key Questions
How much of the fourth-quarter revenue jump is already contracted?
Hitting the middle of the $72–76 million outlook requires $24.6 million in Q4, up $5.3 million from Q3. With deferred revenue down to $0.74 million, investors need to know whether firm enzyme orders or an unsigned licensing fee bridge the gap.
Why did factory construction slip into the new year?
Codexis previously planned to start retrofitting its ECO GMP clinical factory in the second half of 2026 after applying for a permit in Q2. Pushing the start to 2027 compresses the window to get the site running by late 2027.
What are the interest rate and covenants on Trinity's loan?
The $42.5 million drawdown retired the old Innovatus debt just before its February 2027 principal payments began. The filing needs to show when the new loan starts amortizing and what minimum revenue or cash rules apply.
How much revenue did ECO Synthesis generate in Q3?
R&D revenue doubled from last quarter to $3.5 million, while unbilled contract assets jumped by $4.3 million. Management has not yet stated how much of that came from RNA feasibility studies versus older pharmaceutical partnerships.